CPSF73 has been implicated in cancers (gray area of the circle) as a biomarker in lung cancer, as a contributor to pathology of prostate, colorectal, and triple-negative breast cancers, and as a new therapeutic intervention for acute myeloid leukemia (AML) and Ewing’s sarcoma (ES) through the CPSF73-specific inhibitor JTE-607. The blue portion of the circle indicates the use of benzoxaboroles as drugs that specifically inhibit the CPSF73 of protozoan parasites, including Trypanosma, Plasmodium, Cryptosporidium, and Toxoplasma, without affecting mammalian CPSF73.